PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34524494-0 2021 Correction to: IL-15 superagonist N-803 improves IFNgamma production and killing of leukemia and ovarian cancer cells by CD34+ progenitor-derived NK cells. n-803 34-39 interleukin 15 Homo sapiens 15-20 34578331-5 2021 The IL-15 superagonist N-803 was developed to expand the therapeutic potential of IL-15 by maximizing its tissue distribution and half-life. n-803 23-28 interleukin 15 Homo sapiens 4-9 34578331-5 2021 The IL-15 superagonist N-803 was developed to expand the therapeutic potential of IL-15 by maximizing its tissue distribution and half-life. n-803 23-28 interleukin 15 Homo sapiens 82-87 34244306-11 2021 Moreover, we find that fulvestrant pretreatment of tumor cells synergizes with the IL-15 superagonist N-803 treatment of NK cells and sensitizes tumor cells to killing by programmed death-ligand 1 (PD-L1) targeting high-affinity natural killer (t-haNK) cells. n-803 102-107 interleukin 15 Homo sapiens 83-88 34244307-5 2021 N-803 is a superagonist of an interleukin-15 (IL-15) variant bound to an IL-15 receptor alpha Su-Fc fusion with enhanced biological activity. n-803 0-5 interleukin 15 Homo sapiens 30-44 34244307-5 2021 N-803 is a superagonist of an interleukin-15 (IL-15) variant bound to an IL-15 receptor alpha Su-Fc fusion with enhanced biological activity. n-803 0-5 interleukin 15 Homo sapiens 46-51 33140189-0 2021 IL-15 superagonist N-803 improves IFNgamma production and killing of leukemia and ovarian cancer cells by CD34+ progenitor-derived NK cells. n-803 19-24 interleukin 15 Homo sapiens 0-5 35284622-4 2022 N-803 is an IL-15 superagonist composed of an IL-15 mutant (IL-15N72D) bound to the sushi domain of IL-15Ralpha fused to the Fc region of IgG1, which results in physiological trans-presentation of IL-15. n-803 0-5 interleukin 15 Homo sapiens 12-17 35284622-4 2022 N-803 is an IL-15 superagonist composed of an IL-15 mutant (IL-15N72D) bound to the sushi domain of IL-15Ralpha fused to the Fc region of IgG1, which results in physiological trans-presentation of IL-15. n-803 0-5 interleukin 15 Homo sapiens 46-51 35284622-4 2022 N-803 is an IL-15 superagonist composed of an IL-15 mutant (IL-15N72D) bound to the sushi domain of IL-15Ralpha fused to the Fc region of IgG1, which results in physiological trans-presentation of IL-15. n-803 0-5 interleukin 15 Homo sapiens 197-202 35172349-9 2022 N-803 is an interleukin (IL)-15 analogue, which has been investigated in a phase 1b study in combination with BCG and has shown durable complete response in all nine patients for 72 months. n-803 0-5 interleukin 15 Homo sapiens 12-31 35102335-0 2022 Safety and virologic impact of the IL-15 superagonist N-803 in people living with HIV: a phase 1 trial. n-803 54-59 interleukin 15 Homo sapiens 35-40 35102335-2 2022 N-803 is an IL-15 superagonist comprised of an N72D mutant IL-15 molecule attached to its alpha receptor and a human IgG1 fragment designed to increase IL-15 activity. n-803 0-5 interleukin 15 Homo sapiens 12-17 35102335-2 2022 N-803 is an IL-15 superagonist comprised of an N72D mutant IL-15 molecule attached to its alpha receptor and a human IgG1 fragment designed to increase IL-15 activity. n-803 0-5 interleukin 15 Homo sapiens 59-64 35102335-2 2022 N-803 is an IL-15 superagonist comprised of an N72D mutant IL-15 molecule attached to its alpha receptor and a human IgG1 fragment designed to increase IL-15 activity. n-803 0-5 interleukin 15 Homo sapiens 152-157 33140189-5 2021 Therefore, ImmunityBio developed IL-15 superagonist N-803, which combines IL-15 with an activating mutation, an IL-15Ralpha sushi domain for trans-presentation, and IgG1-Fc for increased half-life. n-803 52-57 interleukin 15 Homo sapiens 33-38 33140189-5 2021 Therefore, ImmunityBio developed IL-15 superagonist N-803, which combines IL-15 with an activating mutation, an IL-15Ralpha sushi domain for trans-presentation, and IgG1-Fc for increased half-life. n-803 52-57 interleukin 15 Homo sapiens 74-79 33140189-14 2021 In conclusion, N-803 is a promising IL-15-based compound that boosts HPC-NK cell expansion and functionality in vitro and in vivo. n-803 16-21 interleukin 15 Homo sapiens 37-42 33832946-0 2021 Phase 1 trial of N-803, an IL-15 receptor agonist, with rituximab in patients with indolent non-Hodgkin lymphoma. n-803 17-22 interleukin 15 Homo sapiens 27-32 33832946-1 2021 PURPOSE: N-803 is an IL-15 receptor superagonist complex, designed to optimize in vivo persistence and trans-presentation, thereby activating and expanding natural killer (NK) cells and CD8+ T cells. n-803 9-14 interleukin 15 Homo sapiens 21-26 32484854-0 2020 Interleukin-15 superagonist (N-803) treatment of PML and JCV in a post-allogeneic hematopoietic stem cell transplant patient. n-803 29-34 interleukin 15 Homo sapiens 0-14 32669328-0 2020 Combination of CD8beta depletion and IL-15 superagonist N-803 induces virus reactivation in SHIV-infected, long-term ART-treated rhesus macaques. n-803 56-61 interleukin 15 Homo sapiens 37-42 32913030-0 2020 Complete response to avelumab and IL-15 superagonist N-803 with Abraxane in Merkel cell carcinoma: a case study. n-803 53-58 interleukin 15 Homo sapiens 34-39 32913030-3 2020 Combined therapy with low/moderate dose nab-paclitaxel and an interleukin 15 (IL-15)-based therapeutic such as the IL-15 "superagonist" N-803 may increase response by activation of the immune system. n-803 136-141 interleukin 15 Homo sapiens 62-76 32913030-3 2020 Combined therapy with low/moderate dose nab-paclitaxel and an interleukin 15 (IL-15)-based therapeutic such as the IL-15 "superagonist" N-803 may increase response by activation of the immune system. n-803 136-141 interleukin 15 Homo sapiens 78-83 32913030-3 2020 Combined therapy with low/moderate dose nab-paclitaxel and an interleukin 15 (IL-15)-based therapeutic such as the IL-15 "superagonist" N-803 may increase response by activation of the immune system. n-803 136-141 interleukin 15 Homo sapiens 115-120 32303618-3 2020 N-809 is a first-in-class bifunctional agent comprising the interleukin (IL)-15 superagonist N-803 fused to two alphaPD-L1 domains. n-803 93-98 interleukin 15 Homo sapiens 60-79 32163523-0 2020 The human IL-15 superagonist N-803 promotes migration of virus-specific CD8+ T and NK cells to B cell follicles but does not reverse latency in ART-suppressed, SHIV-infected macaques. n-803 29-34 interleukin 15 Homo sapiens 10-15 32163523-2 2020 The human IL-15 superagonist N-803 (formerly ALT-803) is a promising anti-cancer biologic with potent immunostimulatory properties that has been extended into the field of HIV as a potential "shock and kill" therapeutic for HIV cure. n-803 29-34 interleukin 15 Homo sapiens 10-15